Although PD-L1 tumor proportion score (TPS)(1), microsatellite instability status (MSI)(2) and interferon gamma (IFN-γ)(3) gene signature have been widely recognized as biomarkers to predict the responsiveness of PD-1/PD-L1 blockade treatment, more clinically robust and practical markers are needed to more precisely identify potential responders and also to warn of potential toxicity especially when combination immunotherapies are used. This evidence concerns the gene IFNG and neoplasm.